Rising Prevalence of Psoriasis to Create Scope for North America Interleukin Inhibitors Market

The North America Interleukin Inhibitors market is anticipated to grow significantly at a CAGR of 11.1% over the forecast period (2021-2027). The US and Canada are the two economies contributing to the growth of the market over the forecast period. The key aspect that drives the growth of the North America Interleukin Inhibitors market is the need for advanced treatment options for various diseases such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. There has been increased adoption of IL-17 inhibitors for the treatment of various skin diseases such as psoriasis. The IL-17 inhibitors function as angiogenesis; have a pro-inflammatory role in asthma; increases the inflammatory cytokines; and induces production of IL-4, IL-5, and IL-13, which stimulate eosinophil expansion.

Browse the full report description North America Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027 at https://www.omrglobal.com/industry-reports/north-american-interleukin-inhibitors-market

There has been a significant prevalence of psoriasis among people across the region. According to the Institute for Health Metrics and Evaluation, the prevalence of psoriasis in 2017 was more than 4.6 million which increased up to more than 4.7 million over the forecast period. Further, the clinical trials going on regarding the psoriasis treatment also creates scope for the market. As per the National Clinical Trial (NCT) Registry, more than 200 clinical trials were going on, as of December 2020, regarding the interleukin inhibitors in the US across different phases of development for various indications including psoriasis. 

Market Coverage

• Market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- By Product Type and Applications
• Region Covered- North America
• Competitive Landscape- Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among others

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in base year?
• Which segment will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North America Interleukin Inhibitors Market – Segmentation

By Product Type

• IL-1 Inhibitors
• IL-5 Inhibitors
• IL-6 Inhibitors
• IL-17 Inhibitors
• IL-23 Inhibitors

By Applications

• Arthritis
• Asthma
• Eczema
• Inflammatory Bowel Disease (IBD)
• Psoriasis
• Others

North America Interleukin Inhibitors Market – Countries Covered

North America           

• The US
• Canada